|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
|
Primary Malignant Liver Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that NUAK1 was increased in the tumor of primary liver cancer.
|
30807203 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on these results, we identified miR-204 as a tumor suppressor by inhibiting NUAK1 expression in liver cancer, indicating both miR-204 and NUAK1 may act as promising targets for liver cancer therapy.
|
30807203 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on these results, we identified miR-204 as a tumor suppressor by inhibiting NUAK1 expression in liver cancer, indicating both miR-204 and NUAK1 may act as promising targets for liver cancer therapy.
|
30807203 |
2019 |
|
Malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on these results, we identified miR-204 as a tumor suppressor by inhibiting NUAK1 expression in liver cancer, indicating both miR-204 and NUAK1 may act as promising targets for liver cancer therapy.
|
30807203 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NUAK1 regulates several processes in tumorigenesis; however, its regulation and molecular targets are still poorly understood.
|
31090959 |
2019 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Samples from 60 patients with colon cancer were collected and immunohistochemistry was used to detect the expression of ARK5 and HIF1-α within them.
|
29467884 |
2018 |
|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Deletion of NUAK1 suppresses formation of colorectal tumors, whereas acute depletion of NUAK1 induces regression of preexisting autochthonous tumors.
|
29500295 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer.
|
29106388 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer.
|
29106388 |
2018 |
|
Disseminated Malignant Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer.
|
29106388 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the immunohistochemistry results, ARK5 and HIF1-α staining was significantly associated with Tumor-Node-Metastasis stage, tumor grade, lymph node metastasis and liver metastasis.
|
29467884 |
2018 |
|
Pervasive Development Disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Haploinsufficiency of autism spectrum disorder candidate gene NUAK1 impairs cortical development and behavior in mice.
|
30327473 |
2018 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Samples from 60 patients with colon cancer were collected and immunohistochemistry was used to detect the expression of ARK5 and HIF1-α within them.
|
29467884 |
2018 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, NUAK1 inhibition may be an effective strategy for precision treatment of PTEN-deficient breast tumors.
|
29566768 |
2018 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
Haploinsufficiency of autism spectrum disorder candidate gene NUAK1 impairs cortical development and behavior in mice.
|
30327473 |
2018 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer.
|
29106388 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The elevated ARK5 expression was closely associated with cancer metastasis and patient survival, and it seemed to function in GC cells migration and invasion via EMT alteration, together with the alteration of the mTOR/p70S6k signals, Slug and SIP1, thus providing a potential therapeutic target for GC.
|
28662499 |
2017 |
|
Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that salinomycin reversed the EMT process in cholangiocarcinoma cells by inhibiting ARK5 expression and enhanced the chemosensitivity of cholangiocarcinoma cells to doxorubicin.
|
28832761 |
2017 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The elevated ARK5 expression was closely associated with cancer metastasis and patient survival, and it seemed to function in GC cells migration and invasion via EMT alteration, together with the alteration of the mTOR/p70S6k signals, Slug and SIP1, thus providing a potential therapeutic target for GC.
|
28662499 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.
|
26882562 |
2016 |
|
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
These results demonstrate that decreasing total tau levels is a valid strategy for mitigating tau-related neurodegeneration and reveal Nuak1 to be a novel therapeutic entry point for tauopathies.
|
27720485 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, miR-203 has a tumor-suppressing role in invasion and EMT induction by targeting NUAK1 in HNSCC, suggesting miR-203 as a potential new diagnostic and therapeutic target for the treatment of HNSCC.
|
26882562 |
2016 |